Floatz logo

IPN 60090

Refractory Ovarian High Grade Serous Adenocarcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Refractory Ovarian High Grade Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Olaparib
National Cancer Institute (NCI)
Phase 2CCC
Cediranib
National Cancer Institute (NCI)
Phase 2CCC
Hycamtin
National Cancer Institute (NCI)
Phase 2CCC
Durvalumab
National Cancer Institute (NCI)
Phase 2CCC
Irinotecan
M.D. Anderson Cancer Center
Phase 1CC
Capivasertib
M.D. Anderson Cancer Center
Phase 1CC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

IPN 60090 is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ovarian clear cell adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →